• Home
  • News
  • Stephenson Harwood advises Oxford Biomedica on further Covid-19 vaccine deal

04 Sep 2020

Stephenson Harwood advises Oxford Biomedica on further Covid-19 vaccine deal

Linkedin

Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on a second supply agreement with AstraZeneca, to expand the manufacturing support of Covid-19 vaccine, AZD1222. This agreement builds on the supply agreement between the companies, which was announced on 28 May.

The 18 month agreement with AstraZeneca, part of a three year master supply and development agreement, is for the large-scale commercial manufacture of the adenovirus vector-based Covid-19 vaccine, AZD1222. Under the terms of the agreement, AstraZeneca will pay Oxford Biomedica £15 million as a capacity reservation fee. Subject to satisfactory manufacturing capacity and the continuation of the vaccine programme, Oxford Biomedica will receive additional revenue in excess of £35 million, plus certain material costs.

The Stephenson Harwood team was led by partner Dan Holland, with support from senior associate Chloe Haywood. Further assistance was provided by partners Maryanna Sharrock and Alexandra Pygall, and senior associate Jodie Lilir.

Linkedin

MEDIA CONTACT

Andrew Rieley
Head of communications and PR
T: +44 20 7809 2886
Email Andrew